Development
Recursion Pharmaceuticals, Inc.
RXRX
$5.49
$0.9220.13%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -93.00M | -93.02M | -76.73M | -65.33M | -57.49M |
| Total Depreciation and Amortization | 7.55M | 7.58M | 5.54M | 3.73M | 3.21M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.64M | 16.98M | 13.84M | 12.69M | 10.13M |
| Change in Net Operating Assets | -11.27M | -4.46M | -10.12M | -24.40M | -601.00K |
| Cash from Operations | -74.08M | -72.92M | -67.47M | -73.32M | -44.75M |
| Capital Expenditure | -2.07M | -745.00K | -3.97M | -5.18M | -7.98M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -71.00K | 0.00 | 1.92M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -350.00K | 398.00K | 0.00 | -165.00K | 0.00 |
| Cash from Investing | -2.49M | -347.00K | -2.05M | -5.34M | -7.98M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -694.00K | -24.00K | -24.00K | -24.00K | -23.00K |
| Issuance of Common Stock | 81.35M | 53.79M | 3.81M | 1.95M | 147.28M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 80.66M | 53.77M | 3.79M | 1.92M | 147.26M |
| Foreign Exchange rate Adjustments | 124.00K | -115.00K | 181.00K | -2.00K | -307.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.22M | -19.62M | -65.55M | -76.74M | 94.22M |